GALT (STOCKS)
Galectin Therapeutics Inc.
$2.760000
+0.000000 (+0.00%)
Prev close: $2.760000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Joel Lewis
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $178.61M
- Employees
- 15
- P/E (TTM)
- -4.67
- P/B (TTM)
- -1.41
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.13 | $-0.11 | -0.0178 | -15.86% |
|
Jun 2025 (Q2)
|
$-0.12 | $-0.16 | +0.0432 | +26.47% |
|
Mar 2025 (Q1)
|
$-0.15 | $-0.20 | +0.0540 | +26.47% |
|
Dec 2024 (Q4)
|
$-0.19 | $-0.16 | -0.0268 | -16.42% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | -$8.16M |
| Operating Expenses | $29.15M |
| Research and Development | $23.47M |
| Other Operating Expenses | $5.68M |
| Operating Income/Loss | -$29.15M |
| Income/Loss From Continuing Operations After Tax | -$37.30M |
| Income/Loss From Continuing Operations Before Tax | -$37.30M |
| Net Income/Loss | -$37.30M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$37.30M |
| Net Income/Loss Available To Common Stockholders, Basic | -$37.44M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $139.00K |
| Preferred Stock Dividends And Other Adjustments | $139.00K |
| Basic Earnings Per Share | -$0.59 |
| Diluted Earnings Per Share | -$0.59 |
| Basic Average Shares | 63,769,000 |
| Diluted Average Shares | 63,769,000 |
| Assets | $12.87M |
| Current Assets | $12.73M |
| Noncurrent Assets | $136.00K |
| Liabilities | $136.45M |
| Current Liabilities | $136.45M |
| Accounts Payable | $5.39M |
| Wages | $1.10M |
| Other Current Liabilities | $129.96M |
| Noncurrent Liabilities | $0.00 |
| Equity | -$125.30M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$125.30M |
| Temporary Equity | $1.72M |
| Temporary Equity Attributable To Parent | $1.72M |
| Liabilities And Equity | $12.87M |
| Net Cash Flow From Operating Activities | -$30.62M |
| Net Cash Flow From Operating Activities, Continuing | -$30.62M |
| Net Cash Flow From Investing Activities | $15.54M |
| Net Cash Flow From Investing Activities, Continuing | $15.54M |
| Net Cash Flow From Financing Activities | $15.09M |
| Net Cash Flow From Financing Activities, Continuing | $15.09M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$37.30M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$37.30M |
| Other Comprehensive Income/Loss | $0.00 |